Real-time insights. Smarter decisions. Better trades.
🔍 Search Stocks 14 day Free Trial
RECCE PHARMACEUTICALS LTD (RCE)ASX AI Signals has generated 0 signals for RCE during the last 90 days, indicating low trading activity
RCE Share Price | |
| Current Price | $0.375 |
| 52 Week High | $0.705 |
| 52 Week Low: | $0.305 |
| Trading at (% of 52 Week High) | 53.19% |
Recce Pharmaceuticals Ltd (ASX: RCE) is an Australian biotechnology company focused on developing new antibiotics to treat multi-drug resistant infections. The company uses its proprietary platform to create novel therapies aimed at addressing antimicrobial resistance.
The Pharmaceuticals, Biotechnology & Life Sciences sector on the ASX includes companies involved in the development, production, and commercialization of drugs, medical devices, and biotechnology products. This sector covers activities such as research and development of new medicines, genetic testing, and innovative healthcare technologies. Companies often work on treatments for diseases, including cancer, infectious diseases, and chronic conditions. The sector plays a crucial role in advancing medical science and improving patient care through innovation.
Recce Pharmaceuticals bolsters cash position with A$3.67 million tax refund ahead of Phase 3 milestones Proactive uses images sourced from Shutterstock
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has strengthened its balance sheet with the receipt of a A$3.67 million income tax refund from the A Expansion into the Middle East and North Africa (MENA) region is now firmly in Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF)'s sights after it took a step toward commercialising its R327 Topical Gel, signing a non-binding term sheet with a leading publicly listed Middle Eastern pharmaceutical compa Recce Pharmaceuticals
SYDNEY, Australia, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office has formally granted Recce a new family four patent, “Proce Recce Pharmaceuticals
SYDNEY, Australia, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, is pleased to announce the international cash receipt of A$98,428.27 from the government of Canad Recce Pharmaceuticals
Cohort dosing at Scientia Clinical Research has been completed ahead of schedule Demonstrated RECCE® 327 (R327) to be safe and well-tolerated in male and female subjects at two faster infusion rates of 2,500mg rates via intravenous (IV) administration Independent safety commitLatest RECCE PHARMACEUTICALS LTD(RCE) News
Recce Pharmaceuticals bolsters cash position with A$3.67 million tax refund ahead of Phase 3 milestones
Recce Pharmaceuticals targets Middle East expansion with 10-year R327G licensing deal
Recce Pharmaceuticals Granted New Anti-Viral Patent in Australia for RECCE® Anti-Infectives
Recce Pharmaceuticals Receives Second Canadian Scientific Research and Experimental Development Rebate
Recce Pharmaceuticals Completes First Cohort Dosing of Phase l/ll UTI Rapid Infusion Clinical Trial at Scientia Clinical Research
Get access to daily BUY & SELL signals, advanced AI analysis, watchlists and email alerts.
14 Day Free Trial • Cancel Anytime • Founders Price $15/month
Start My Free Trial